I was uncomfortable saying this before due to lack of studies, but now that the Keto-CTA (LMHR) study has been published, it is crystal clear:
If you have significant plaque and go on a keto diet that significantly raises your LDL, then you are very likely to see progression of that plaque if you are lean and metabolically healthy.
Being lean and metabolically healthy will NOT protect you from the potential harm that this diet may cause in people with existing atherosclerosis.
The Keto-CTA (LMHR) study has definitively proven this:
↪ Keto-CTA (LMHR): very high LDL keto dieters with plaque kept progressing despite lean
Lean metabolically-healthy people on keto saw an increase in total plaque volume of 0.8% after only one year in this study. (See comments for chart.)
This is considerably worse than the plaque progression that the average American sees per year.
The average American is significantly overweight, sedentary, and eats the standard American diet loaded with ultra-processed junk food.
Major plaque progression is the reason why 20% of Americans will have a heart attack in their lifetime.
If you look only at people with CAC scores over 100 in the LMHR study, they saw plaque volume increase by a whopping 2.4% in one year on the keto diet! (See comments for chart.)
If you look only at people with 10 year risk greater than 5% on the standard AHA calculator, they saw an increase in plaque volume of 1.4% in one year on keto, regardless of their CAC score at baseline! (See comments for chart.)
These results are terrible.
Compare these results showing significant plaque progression on keto diets to large randomized controlled trials of the traditional Mediterranean diet plus statins. These trials not only showed that plaque progression halts— they even showed regression.
↪ CORDIOPREV: Mediterranean diet shrank carotid plaque and cut recurrent events about 25%
↪ PREDIMED: nuts regressed carotid plaque and a nut-rich Mediterranean diet cut stroke 50%
↪ Intensive statin reversed atherosclerosis on IVUS in a 2004 Cleveland Clinic-led trial
↪ Meta-analysis: lipid-lowering therapy regresses coronary plaque (Li 2021, SATURN)
↪ Plaque regression: about half at LDL near 80, 90% of regressable plaques below 60
↪ Statin plaque regression RCTs: SATURN, REVERSAL, ASTEROID, COSMOS, JAPAN-ACS
↪ Statin studies on plaque regression, with a link to a longer blog post

